RefleXion Medical is on a mission to create a new cancer treatment modality through biological guidance. By leveraging positron emission tomography (PET) in a novel way, RefleXion’s patented technology causes tumors to continuously signal their location during treatment, potentially revolutionizing cancer care.

Potential Meets Values & Execution

A relevant mission is the cornerstone of any game-changing company, but having the values to execute is the key to long-term success. At RefleXion, our core values are present in everything we do.

Significant Innovation in Localized Cancer Treatment

With a bold mission and dedication to build a high-performing business, RefleXion has inspired the confidence of blue-chip investors, all committed to advancing a new modality in cancer care. RefleXion has raised over $160M in funding from premier investment firms including TPG Growth / The Rise Fund, Sofinnova Partners, KCK Group, Pfizer Venture Investments, Venrock, Johnson & Johnson Innovation, T. Rowe Price Associates and GT Healthcare Capital Partners. The National Cancer Institute (NCI) also provided grant funding through its Small Business Innovation Research (SBIR) Program.

We invite you to learn more about the team we have supporting the effort.